v3.26.1
Segment Reporting - Schedule of reportable segment net (loss) income (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Grant revenue $ 358 $ 0
Operating Expenses 21,265 27,236
Gain on sale of VOWST Business 0 52,181
Net (loss) income (19,913) 32,682
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Grant revenue 358 0
R&D personnel-related (including stock-based compensation) 5,920 6,118
G&A personnel-related (including stock-based compensation) 3,291 4,173
Professional fees 1,714 3,180
Facility-related and other 3,065 4,535
Gain on sale of VOWST Business [1] 0 (52,181)
Other segment (income) expense [2] (899) (4,207)
Net (loss) income (19,913) 32,682
Live Biotherapeutics Platform [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Operating Expenses 6,533 5,123
SER-155 [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Operating Expenses $ 647 $ 577
[1] See Note 3, Discontinued Operations and TSA, for further details.
[2]

[1] Other segment (income) expense includes manufacturing services expenses, research and development expenses on early stage programs, interest income and other (income) expense, net.